KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Deferred Revenue: 2020-2024

Historic Current Deferred Revenue for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $19.2 million.

  • AbCellera Biologics' Current Deferred Revenue rose 57.46% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.5 million, marking a year-over-year increase of 57.46%. This contributed to the annual value of $19.2 million for FY2024, which is 29.21% down from last year.
  • Per AbCellera Biologics' latest filing, its Current Deferred Revenue stood at $19.2 million for FY2024, which was down 29.21% from $27.2 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Current Deferred Revenue registered a high of $41.1 million during FY2022, and its lowest value of $19.2 million during FY2024.
  • Moreover, its 3-year median value for Current Deferred Revenue was $27.2 million (2023), whereas its average is $29.2 million.
  • In the last 5 years, AbCellera Biologics' Current Deferred Revenue spiked by 59.61% in 2021 and then slumped by 33.98% in 2023.
  • Yearly analysis of 5 years shows AbCellera Biologics' Current Deferred Revenue stood at $21.9 million in 2020, then skyrocketed by 59.61% to $35.0 million in 2021, then increased by 17.66% to $41.1 million in 2022, then crashed by 33.98% to $27.2 million in 2023, then declined by 29.21% to $19.2 million in 2024.